Compare ZVIA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | ACRS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.4M | 311.0M |
| IPO Year | 2021 | 2015 |
| Metric | ZVIA | ACRS |
|---|---|---|
| Price | $1.27 | $3.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.93 | ★ $9.75 |
| AVG Volume (30 Days) | 591.8K | ★ 2.4M |
| Earning Date | 05-25-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.88 | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | $1,683,000.00 |
| Revenue This Year | $8.33 | N/A |
| Revenue Next Year | $6.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $1.05 |
| 52 Week High | $3.66 | $4.89 |
| Indicator | ZVIA | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 60.99 |
| Support Level | $1.11 | $2.67 |
| Resistance Level | $2.76 | $3.78 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 37.08 | 89.40 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.